Biotech & Pharma

Watch: Who won the Hims vs. Novo feud?

33 sec read12 views0 listens

Novo Nordisk and Hims & Hers have resolved their feud by agreeing on a deal that allows Hims to sell Novo's weight loss drugs at a discount while limiting its compounding activities, leading to the dismissal of legal proceedings; this move is seen positively by regulators but raises questions about long-term impacts on the drug ecosystem. Content creators and analysts will discuss the implications for the health tech industry, focusing on the deal’s winners and losers and the credibility of Hims' commitment to reduced compounding.

Read the full article at Endpoints News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Health & Medicine2 days ago26 sec read

The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don't Qualify

Medicare's GLP-1 discount program, aimed at helping obese patients afford weight loss medications, excludes those with certain medical conditions like sleep apnea, despite these individuals often having the highest need for such drugs. This exclusion...

Ali Nemati

Fitness & WellnessAug 2128 sec read

EP95 | Getting Ready For Sydney

The latest episode of Marathon Talk focuses on the upcoming TCS Sydney Marathon and features an interview with Australian marathon legend Lisa Weightman. This episode is crucial for developers and tech professionals interested in fitness technology, ...

Ali Nemati

Fitness & WellnessAug 2029 sec read

'These Neurons Are an Underlying Problem When It Comes to Narcolepsy'

Researchers have identified a specific group of GABA neurons in the brainstem that act as a switch to induce sleep and suppress wakefulness. This discovery is significant for developers and researchers in the health tech and neuroscience fields as it...

Ali Nemati